Prospective Registry‐Based Observational Cohort Study of the Long‐Term Risk of Malignancies in Renal Transplant Patients Treated with Mycophenolate Mofetil
Open Access
- 18 November 2005
- journal article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 5 (12), 2954-2960
- https://doi.org/10.1111/j.1600-6143.2005.01125.x
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1Transplantation, 2003
- Immunosuppressive drugs and cancerToxicology, 2003
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Mycophenolate MofetilDrugs, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995
- Progress in Renal Transplantation A Single Center Study of 3359 Patients Over 25 YearsAnnals of Surgery, 1995
- Triple therapy and incidence of de novo cancer in renal transplant recipientsBritish Journal of Surgery, 1994
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsThe New England Journal of Medicine, 1990